{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:22:47Z","timestamp":1791120167188,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1124\/jpet.105.084202","type":"journal-article","created":{"date-parts":[[2005,8,20]],"date-time":"2005-08-20T00:53:26Z","timestamp":1124499206000},"page":"1248-1256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Sumanirole, a Highly Dopamine D2-Selective Receptor Agonist: In Vitro and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"314","author":[{"given":"Robert B.","family":"McCall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Lookingland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita M.","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.105.084202_bib1","doi-asserted-by":"crossref","unstructured":"Bedard PJ, Di Paolo T, Falardeau P, and Boucher R (1986) Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]-spiperone binding. Brain Res 379: 294-299.","DOI":"10.1016\/0006-8993(86)90783-3"},{"key":"10.1124\/jpet.105.084202_bib2","doi-asserted-by":"crossref","unstructured":"Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, and Schwartz JC (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564: 203-219.","DOI":"10.1016\/0006-8993(91)91456-B"},{"key":"10.1124\/jpet.105.084202_bib3","doi-asserted-by":"crossref","unstructured":"Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Musch BC, and the PKDS009 Study Group (2004) The long-acting dopamine receptor agonist cabergoline in early Parkinson\u2019s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18: 733-746.","DOI":"10.2165\/00023210-200418110-00003"},{"key":"10.1124\/jpet.105.084202_bib4","doi-asserted-by":"crossref","unstructured":"Bunney BS, Walters JR, Roth RH, and Aghajanian GK (1973) Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185: 560-571.","DOI":"10.1016\/S0022-3565(25)29539-8"},{"key":"10.1124\/jpet.105.084202_bib5","doi-asserted-by":"crossref","unstructured":"Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, and Civelli O (1988) Cloning and expression of a rat D2 dopamine receptor cDNA. Nature (Lond) 336: 783-787.","DOI":"10.1038\/336783a0"},{"key":"10.1124\/jpet.105.084202_bib6","doi-asserted-by":"crossref","unstructured":"Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, and Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546-4550.","DOI":"10.1073\/pnas.80.14.4546"},{"key":"10.1124\/jpet.105.084202_bib7","doi-asserted-by":"crossref","unstructured":"Carlsson A, Lindqvist M, and Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature (Lond) 180: 1200.","DOI":"10.1038\/1801200a0"},{"key":"10.1124\/jpet.105.084202_bib8","doi-asserted-by":"crossref","unstructured":"Cheng YC and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"10.1124\/jpet.105.084202_bib9","doi-asserted-by":"crossref","unstructured":"Chio CL, Drong RF, Riley DT, Gill GS, Slightom JL, and Huff RM (1994a) D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J Biol Chem 269: 11813-11819.","DOI":"10.1016\/S0021-9258(17)32645-5"},{"key":"10.1124\/jpet.105.084202_bib10","doi-asserted-by":"crossref","unstructured":"Chio CL, Lajiness ME, and Huff RM (1994b) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 45: 51-60.","DOI":"10.1016\/S0026-895X(25)09903-1"},{"key":"10.1124\/jpet.105.084202_bib11","doi-asserted-by":"crossref","unstructured":"Civelli O, Bunzow JR, and Grandy DK (1993) Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 33: 281-307.","DOI":"10.1146\/annurev.pa.33.040193.001433"},{"key":"10.1124\/jpet.105.084202_bib12","doi-asserted-by":"crossref","unstructured":"Consolo S, Wu CF, Fiorentini F, Ladinsky H, and Vezzani A (1987) Determination of endogenous acetylcholine release in freely moving rats by transstriatal dialysis coupled to a radioenzymatic assay: effect of drugs. J Neurochem 48: 1459-1465.","DOI":"10.1111\/j.1471-4159.1987.tb05686.x"},{"key":"10.1124\/jpet.105.084202_bib13","doi-asserted-by":"crossref","unstructured":"De Keyser J, De Backer JP, Wilczak N, and Herroelen L (1995) Dopamine agonists used in the treatment of Parkinson\u2019s disease and their selectivity for the D1, D2 and D3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry 19: 1147-1154.","DOI":"10.1016\/0278-5846(95)00232-4"},{"key":"10.1124\/jpet.105.084202_bib14","doi-asserted-by":"crossref","unstructured":"Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME, Naylor RJ, Owen DA, and Wright A (1991) Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 38: 147-154.","DOI":"10.1016\/0091-3057(91)90603-Y"},{"key":"10.1124\/jpet.105.084202_bib15","doi-asserted-by":"crossref","unstructured":"Etminan M, Gill S, and Samii A (2003) Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson\u2019s disease: a meta-analysis. Drug Safety 26: 439-444.","DOI":"10.2165\/00002018-200326060-00005"},{"key":"10.1124\/jpet.105.084202_bib16","unstructured":"Friedman JH (1995) Management of psychosis in Parkinson\u2019s disease, in Therapy of Parkinson\u2019s Disease (Koller WC and Paulson G eds) pp 521-532, Marcel Dekker, New York."},{"key":"10.1124\/jpet.105.084202_bib17","doi-asserted-by":"crossref","unstructured":"Gomez-Mancilla B, Boucher R, Gagnon C, Di Paolo T, Markstein R, and Bedard PJ (1993) Effect of adding the D1 agonist Cy 208-243 to chronic bromocriptine treatment. I: evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Mov Disord 8: 144-150.","DOI":"10.1002\/mds.870080205"},{"key":"10.1124\/jpet.105.084202_bib18","doi-asserted-by":"crossref","unstructured":"Hagan JJ, Middlemiss DR, Sharpe PC, and Poste GH (1997) Parkinson\u2019s disease: prospects for improved drug therapy. Trends Pharmacol Sci 18: 156-163.","DOI":"10.1016\/S0165-6147(97)90612-X"},{"key":"10.1124\/jpet.105.084202_bib19","doi-asserted-by":"crossref","unstructured":"Heier RF, Dolak LA, Duncan JN, Hyslop DK, Lipton MF, Martin IJ, Mauragis MA, Piercey MF, Nichols NF, Schreur PJK, et al. (1997) Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinoline-5-amine and its metabolites. J Med Chem 40: 639-646.","DOI":"10.1021\/jm960360q"},{"key":"10.1124\/jpet.105.084202_bib20","doi-asserted-by":"crossref","unstructured":"Ho KY and Thorner MO (1988) Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 36: 67-82.","DOI":"10.2165\/00003495-198836010-00005"},{"key":"10.1124\/jpet.105.084202_bib21","doi-asserted-by":"crossref","unstructured":"Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, and Fleming J (2002) Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. J Am Med Assoc 287: 455-463.","DOI":"10.1001\/jama.287.4.455"},{"key":"10.1124\/jpet.105.084202_bib22","doi-asserted-by":"crossref","unstructured":"Inzelberg R, Schechtman E, and Nisipeanu P (2003) Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson\u2019s disease: an evidence-based comparison. Drugs Aging 20: 847-855.","DOI":"10.2165\/00002512-200320110-00006"},{"key":"10.1124\/jpet.105.084202_bib23","doi-asserted-by":"crossref","unstructured":"Lagos P, Scorza C, Monti JM, Jantos H, Reyes-Parada M, Silveira R, and Ponzoni A (1998) Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats. Eur Neuropsychopharmacol 8: 113-120.","DOI":"10.1016\/S0924-977X(97)00054-0"},{"key":"10.1124\/jpet.105.084202_bib24","doi-asserted-by":"crossref","unstructured":"Lahti RA, Evans DL, Figur LM, Carrigan KJ, Moon MW, and Hsi RS (1991) Dopamine D2 receptor binding properties of [3H]U-86170, a dopamine receptor agonist. Eur J Pharmacol 202: 289-291.","DOI":"10.1016\/0014-2999(91)90308-D"},{"key":"10.1124\/jpet.105.084202_bib25","doi-asserted-by":"crossref","unstructured":"Lajiness ME, Chio CL, and Huff RM (1994) D2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylations. J Pharmacol Exp Ther 267: 1573-1581.","DOI":"10.1016\/S0022-3565(25)39451-6"},{"key":"10.1124\/jpet.105.084202_bib26","unstructured":"Lieberman A (1995) Dopamine agonists in Parkinson\u2019s disease, in Therapy of Parkinson\u2019s Disease (Koller WC and Paulson G eds) pp 199-208, Marcel Dekker, New York."},{"key":"10.1124\/jpet.105.084202_bib27","doi-asserted-by":"crossref","unstructured":"Meador-Woodruff JH, Mansour A, Bunzow JR, VanTol HH, Watson SJ, and Civelli O (1989) Distribution of D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA 86: 7625-7628.","DOI":"10.1073\/pnas.86.19.7625"},{"key":"10.1124\/jpet.105.084202_bib28","doi-asserted-by":"crossref","unstructured":"Missale C, Castelletti L, Boroni F, Memo M, and Spano P (1991) Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line. Endocrinology 128: 13-20.","DOI":"10.1210\/endo-128-1-13"},{"key":"10.1124\/jpet.105.084202_bib29","doi-asserted-by":"crossref","unstructured":"Montastruc JL, Rascol O, and Senard JM (1993) Current status of dopamine agonists in Parkinson\u2019s disease management. Drugs 46: 384-393.","DOI":"10.2165\/00003495-199346030-00005"},{"key":"10.1124\/jpet.105.084202_bib30","unstructured":"Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney."},{"key":"10.1124\/jpet.105.084202_bib31","unstructured":"Pellegrino LJ, Pellegrino AS, and Cushman AJ (1979) A Stereotaxic Atlas of the Rat Brain. Plenum Press, New York."},{"key":"10.1124\/jpet.105.084202_bib32","doi-asserted-by":"crossref","unstructured":"Piercey MF, Hoffmann WE, Smith MW, and Hyslop DK (1996a) Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312: 35-44.","DOI":"10.1016\/0014-2999(96)00454-2"},{"key":"10.1124\/jpet.105.084202_bib33","doi-asserted-by":"crossref","unstructured":"Piercey MF, Moon MW, Sethy VH, Schreur PJ, Tang AH, and VonVoigtlander PF (1996b) Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype. Eur J Pharmacol 317: 29-38.","DOI":"10.1016\/S0014-2999(96)00695-4"},{"key":"10.1124\/jpet.105.084202_bib34","doi-asserted-by":"crossref","unstructured":"Pinnock RD (1984) The actions of antipsychotic drugs on dopamine receptors in the rat substantia nigra. Br J Pharmacol 81: 631-635.","DOI":"10.1111\/j.1476-5381.1984.tb16128.x"},{"key":"10.1124\/jpet.105.084202_bib35","unstructured":"Rascol O, Lees AJ, Senard JM, Pirtosek Z, Brefel C, Montastruc JL, and Fuell D (1996) A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Adv Neurol 69: 531-534."},{"key":"10.1124\/jpet.105.084202_bib36","doi-asserted-by":"crossref","unstructured":"Razmy A, Lang AE, and Shapiro CM (2004) Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 61: 97-102.","DOI":"10.1001\/archneur.61.1.97"},{"key":"10.1124\/jpet.105.084202_bib37","doi-asserted-by":"crossref","unstructured":"Sethy VH (1979) Regulation of striatal acetylcholine concentration by D2-dopamine receptors. Eur J Pharmacol 60: 397-398.","DOI":"10.1016\/0014-2999(79)90252-8"},{"key":"10.1124\/jpet.105.084202_bib38","doi-asserted-by":"crossref","unstructured":"Sokoloff P, Giros B, Martres MP, Bouthenet ML, and Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (Lond) 347: 146-151.","DOI":"10.1038\/347146a0"},{"key":"10.1124\/jpet.105.084202_bib39","doi-asserted-by":"crossref","unstructured":"Stephenson DT, Meglasson MD, Connell MA, Childs MA, Hajos-Korcsok E, and Emborg ME (2005) The effects of a selective dopamine D2 receptor agonist on behavioral and pathologic outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys. J Pharmacol Exp Ther 314: 1257-1266.","DOI":"10.1124\/jpet.105.087379"},{"key":"10.1124\/jpet.105.084202_bib40","doi-asserted-by":"crossref","unstructured":"Ungerstedt U (1971) Postsynaptic supersensitivity after 6-OHDA induced degeneration of the nigra-striatal dopamine system. Acta Physiol Scand 367: 69-93.","DOI":"10.1111\/j.1365-201X.1971.tb11000.x"},{"key":"10.1124\/jpet.105.084202_bib41","doi-asserted-by":"crossref","unstructured":"Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, and Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature (Lond) 350: 610-614.","DOI":"10.1038\/350610a0"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524322001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524322001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.105.084202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:33:41Z","timestamp":1740000821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524322001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0022356524322001"],"URL":"https:\/\/doi.org\/10.1124\/jpet.105.084202","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sumanirole, a Highly Dopamine D2-Selective Receptor Agonist: In Vitro and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.105.084202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}